Four new multiple kinase inhibitors in the clinical trial stage for HER+
http://pubs.acs.org/cen/coverstory/84/8432cancer.html
August 7, 2006 Battling Breast Cancer By targeting multiple HER-family receptors, small-molecule drugs could fill the therapeutic gaps left by Herceptin In this informative article the expected mode of action of 4 new drugs in clinical trials is explained. They will hopefully be even more effective than Herceptin or Tykerb as they are supposed to inhibit two or more pathways & some growth factors & they could become follow up treatments to the 2 proven drugs when resistance sets in. The current temporary name of these drugs is: HKI-272.............Wyeth ...................(lung, breast cancers) XL647.................Exelixis/genentech.. (breast) ARRY-334543......Array Biopharma ......(lung,breast) Pertuzumab........Genentech............. (breast) |
Great article! Thank you.
|
Excellent article, I read it yesterday and was going to post it just now but see you have!
|
All times are GMT -7. The time now is 07:09 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021